Beta Drugs Ltd. engages in the manufacturing and trading of pharmaceuticals. The company is headquartered in Panchkula, Haryana. The company went IPO on 2017-10-12. The firm offers a range of oncology products including tablets, capsules and injections. The firm offers a portfolio consisting of approximately 50 products catering to various oncology diseases, including breast, brain, bone, lung, mouth, head and neck, prostate, leukemia, lymphoma and supportive cancer and others. The Company’s oncology portfolio includes various brands, such as AB-PACLI, ADBIRON, ADCARB, ADCIST, Adlante, ADLEAP, ADMIDE, ADOXI, CAPAD, ADTHAL, Triodelta and others.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.
23 fields couldn't be derived. The company was scraped before the cash-flow and balance-sheet rows were captured. Re-running an analysis will refresh these.